Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation

European Urology

Volumn 44, Issue 2, 2003, Pages 222-225

  Pieras, E ^a   Palou, J ^a   Salvador, J ^a   Rosales, A ^a   Marcuello, E ^b   Villavicencio, H ^a   Van der Meijden, A ^c  

^a FUNDACIÓ PUIGVERT   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c NONE

Author keywords

BCG; Bladder preservation; Invasive; Superficial recurrence; Transitional cell carcinoma; Transurethral resection

Indexed keywords

BCG VACCINE; CARBOPLATIN; MITOMYCIN; VINBLASTINE;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONSERVATIVE TREATMENT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 0042268033     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00258-6     Document Type: Article

References (15)

1. Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol 2000;164:627-32.
2. Shipley WU, Kaufman DS, Heney NM, et al. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 1999;162:445-51.
3. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111-6.
4. Herr H. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001;19:89-93.
5. Herr H, Bajorin D, Scher H. I. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998;16:1298-300.
6. Schultz PK, Herr HW, Zhang Z, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994;12:1394-401.
7. Angulo JC, Sánchez-Chapado M, López JI, et al. Primary Cisplatin, Methotrexate and Vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. J Urol 1996;155:1897-902.
8. Uygur MC, Yaman I, Altug U, et al. Conservative management of stage T2 or T3a bladder cancer with deep transurethral resection followed by four cycles of chemotherapy. Br J Urol 1996;78:201-4.
9. Given RW, Parsons JT, McCarley D, et al. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 1995;46(4):499-504.
10. Solsona E, Iborra I, Ricos J, et al. Feasibility of transurethral resection for muscle infiltralting carcinoma of the bladder: prospective study. J Urol 1992;147:1513-5.
11. Fellin G, Graffer U, Bolner A, et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol 1997;80:44-9.
12. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58:380-5.
13. Millán F, Chéchile G, Salvador J, et al. Primary superficial bladder cancer risks groups according to progression, recurrence and mortality. J Urol 2000;163(4):1528.
14. Herr H. Tumor progression and survival of patients with high grade, non-invasive papillary bladder tumor: 15 year outcome. J Urol 2000;163:60-2.
15. Solsona E, Iborra I, Ricos JV, et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long term follow up of a prospective study. J Urol 1998;159(1):95-8.